Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finite duration treatment in pre-cirrhotic chronic hepatitis B: lamivudine priming of Pegasys in HBeAg-positive patients
2005-005849-19Phase 4Terminated
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Feb 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of interferon alfa and lamivudine in Chronic Hepatitis B (CHB) (3 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Serious or life-threatening adverse events. Started Feb 2006; status: terminated.
02
Drugs
interferon alfalamivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2005-005849-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005849-19.